Short Wave Folgen

In the first week of COP26, the UN climate conference, world leaders took to the podium to talk about what their countries are going to do to fight climate change. They made big pledges, but protestors in the streets call their promises "greenwashing" and are calling for more action. Joining the show from Glasgow, Scotland, NPR science correspondent, Dan Charles, talks about how the conference is going. Will the diplomats follow the science on climate change? And will the nations of the world follow through on their pledges to cut greenhouse gas emissions?Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

When we lose someone or something we love, it can feel like we've lost a part of ourselves. And for good reason--our brains are learning how to live in the world without someone we care about in it. Host Emily Kwong talks with psychologist Mary-Frances O'Connor about the process our brains go through when we experience grief. Her book, The Grieving Brain: The Surprising Science of How We Learn from Love and Loss, publishes February 1, 2022.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent Jon Hamilton explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.Additional links:- Jon's reporting on aducanumab: https://n.pr/3bDV0MY- Jon's reporting on future Alzheimer's treatments: https://n.pr/3bDUsqoYou can always reach the show by emailing shortwave@npr.org.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy